{"product_id":"enclomiphene-50x12-5mg","title":"Enclomiphene Citrate 100x12.5mg","description":"\u003cp class=\"\" data-end=\"897\" data-start=\"380\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                        \u003cspan style=\"text-decoration: underline;\"\u003eNOT FOR HUMAN \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eCONSUMPTIO\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"46\" data-end=\"694\"\u003e\u003cstrong\u003eEnclomiphene\u003c\/strong\u003e is the \u003cstrong data-start=\"99\" data-end=\"119\"\u003etrans (E) isomer\u003c\/strong\u003e of clomiphene citrate and acts as a \u003cstrong data-start=\"156\" data-end=\"204\"\u003eselective estrogen-receptor modulator (SERM)\u003c\/strong\u003e. In men, it \u003cstrong data-start=\"217\" data-end=\"257\"\u003eblocks estradiol’s negative feedback\u003c\/strong\u003e at the hypothalamus\/pituitary, \u003cstrong data-start=\"289\" data-end=\"314\"\u003eraising GnRH → LH\/FSH\u003c\/strong\u003e, which in turn \u003cstrong data-start=\"330\" data-end=\"368\"\u003estimulates endogenous testosterone\u003c\/strong\u003e production by Leydig cells while \u003cstrong data-start=\"402\" data-end=\"433\"\u003emaintaining spermatogenesis\u003c\/strong\u003e (via FSH\/Sertoli). Unlike \u003cstrong data-start=\"460\" data-end=\"486\"\u003eexogenous testosterone\u003c\/strong\u003e, enclomiphene \u003cstrong data-start=\"501\" data-end=\"535\"\u003edoes not suppress the HPG axis\u003c\/strong\u003e and is commonly used \u003cstrong data-start=\"557\" data-end=\"570\"\u003eoff-label\u003c\/strong\u003e for men with functional\/secondary hypogonadism who desire fertility preservation. (Not FDA\/EMA-approved as a branded drug.)\u003c\/p\u003e\n\u003chr data-start=\"696\" data-end=\"699\"\u003e\n\u003ch3 data-start=\"701\" data-end=\"764\"\u003eAdditional Benefits of Enclomiphene Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"766\" data-end=\"2562\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"766\" data-end=\"794\"\u003e\n\u003ctr data-start=\"766\" data-end=\"794\"\u003e\n\u003cth data-start=\"766\" data-end=\"776\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"776\" data-end=\"794\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"805\" data-end=\"2562\"\u003e\n\u003ctr data-start=\"805\" data-end=\"1051\"\u003e\n\u003ctd data-start=\"805\" data-end=\"872\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"807\" data-end=\"871\"\u003e1 Restores physiologic testosterone with fertility preserved\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"872\" data-end=\"1051\"\u003eIn men with secondary hypogonadism, enclomiphene increases \u003cstrong data-start=\"933\" data-end=\"942\"\u003eTT\/FT\u003c\/strong\u003e to mid-normal while \u003cstrong data-start=\"963\" data-end=\"1004\"\u003emaintaining or improving sperm counts\u003c\/strong\u003e, unlike TRT which often induces azoospermia.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1052\" data-end=\"1246\"\u003e\n\u003ctd data-start=\"1052\" data-end=\"1090\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1054\" data-end=\"1089\"\u003e2 Normalizes LH\/FSH pulsatility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1090\" data-end=\"1246\"\u003eImproves \u003cstrong data-start=\"1101\" data-end=\"1129\"\u003epituitary responsiveness\u003c\/strong\u003e and diurnal \u003cstrong data-start=\"1142\" data-end=\"1147\"\u003eT\u003c\/strong\u003e dynamics (morning peak), supporting libido\/energy improvements without exogenous androgen peaks.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1247\" data-end=\"1437\"\u003e\n\u003ctd data-start=\"1247\" data-end=\"1291\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1249\" data-end=\"1290\"\u003e3 Metabolic profile neutrality vs TRT\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1291\" data-end=\"1437\"\u003eGenerally \u003cstrong data-start=\"1303\" data-end=\"1321\"\u003eweight-neutral\u003c\/strong\u003e with \u003cstrong data-start=\"1327\" data-end=\"1350\"\u003emodest improvements\u003c\/strong\u003e in insulin sensitivity\/lipids in some cohorts; far less \u003cstrong data-start=\"1407\" data-end=\"1425\"\u003eerythrocytosis\u003c\/strong\u003e than TRT.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1438\" data-end=\"1596\"\u003e\n\u003ctd data-start=\"1438\" data-end=\"1481\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1440\" data-end=\"1480\"\u003e4 Symptom relief (sexual \u0026amp; vitality)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1481\" data-end=\"1596\"\u003eReported gains in \u003cstrong data-start=\"1501\" data-end=\"1556\"\u003esexual desire, erectile function, mood, and fatigue\u003c\/strong\u003e parallel biochemical T normalization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1597\" data-end=\"1795\"\u003e\n\u003ctd data-start=\"1597\" data-end=\"1623\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1599\" data-end=\"1622\"\u003e5 Estradiol balance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1623\" data-end=\"1795\"\u003eOften yields \u003cstrong data-start=\"1638\" data-end=\"1656\"\u003ephysiologic E2\u003c\/strong\u003e via aromatization of endogenous T; avoids extreme E2 suppression seen with AIs. \u003cstrong data-start=\"1737\" data-end=\"1760\"\u003eAromatase inhibitor\u003c\/strong\u003e can be added if E2 becomes high.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1796\" data-end=\"1962\"\u003e\n\u003ctd data-start=\"1796\" data-end=\"1834\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1798\" data-end=\"1833\"\u003e6 Testicular volume maintenance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1834\" data-end=\"1962\" data-col-size=\"xl\"\u003eBy stimulating intratesticular T, enclomiphene helps \u003cstrong data-start=\"1889\" data-end=\"1917\"\u003epreserve testicular size\u003c\/strong\u003e vs the shrinking frequently seen with TRT.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1963\" data-end=\"2121\"\u003e\n\u003ctd data-start=\"1963\" data-end=\"1994\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1965\" data-end=\"1993\"\u003e7 Transition off AAS\/TRT\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1994\" data-end=\"2121\"\u003eUsed in post-cycle or TRT cessation plans to \u003cstrong data-start=\"2041\" data-end=\"2062\"\u003ere-start the axis\u003c\/strong\u003e (with or without hCG); evidence is mainly observational.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2122\" data-end=\"2300\"\u003e\n\u003ctd data-start=\"2122\" data-end=\"2167\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2124\" data-end=\"2166\"\u003e8 Sleep apnea\/BP neutrality (relative)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2167\" data-end=\"2300\"\u003eLess fluid retention and hematocrit rise than TRT → \u003cstrong data-start=\"2221\" data-end=\"2235\"\u003elower risk\u003c\/strong\u003e of OSA or BP worsening; still monitor in predisposed patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2301\" data-end=\"2562\"\u003e\n\u003ctd data-start=\"2301\" data-end=\"2343\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2303\" data-end=\"2342\"\u003e9 Female applications (exploratory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2343\" data-end=\"2562\"\u003eIn women, clomiphene is established for ovulation induction; \u003cstrong data-start=\"2406\" data-end=\"2431\"\u003eenclomiphene-specific\u003c\/strong\u003eprograms explored \u003cstrong data-start=\"2450\" data-end=\"2473\"\u003eovulation induction\u003c\/strong\u003e with a \u003cstrong data-start=\"2481\" data-end=\"2511\"\u003eshorter tissue persistence\u003c\/strong\u003e vs zuclomiphene, but it is not standard of care.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2564\" data-end=\"2567\"\u003e\n\u003ch2 data-start=\"2569\" data-end=\"2604\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2606\" data-end=\"2641\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"2642\" data-end=\"2982\"\u003e\n\u003cli data-start=\"2642\" data-end=\"2740\"\u003e\n\u003cp data-start=\"2644\" data-end=\"2740\"\u003e\u003cstrong data-start=\"2644\" data-end=\"2672\"\u003eSERM activity (ERα\/ERβ):\u003c\/strong\u003e \u003cstrong data-start=\"2673\" data-end=\"2687\"\u003eAntagonist\u003c\/strong\u003e at hypothalamus\/pituitary → \u003cstrong data-start=\"2716\" data-end=\"2737\"\u003e↑ GnRH → ↑ LH\/FSH\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2741\" data-end=\"2825\"\u003e\n\u003cp data-start=\"2743\" data-end=\"2825\"\u003e\u003cstrong data-start=\"2743\" data-end=\"2754\"\u003eTestis:\u003c\/strong\u003e \u003cstrong data-start=\"2755\" data-end=\"2785\"\u003eLH → Leydig → testosterone\u003c\/strong\u003e; \u003cstrong data-start=\"2787\" data-end=\"2822\"\u003eFSH → Sertoli → spermatogenesis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2826\" data-end=\"2982\"\u003e\n\u003cp data-start=\"2828\" data-end=\"2982\"\u003e\u003cstrong data-start=\"2828\" data-end=\"2861\"\u003eEnclomiphene vs zuclomiphene:\u003c\/strong\u003e Enclomiphene has \u003cstrong data-start=\"2879\" data-end=\"2929\"\u003eshorter half-life, less estrogenic persistence\u003c\/strong\u003e, and a \u003cstrong data-start=\"2937\" data-end=\"2971\"\u003ecleaner antiestrogenic profile\u003c\/strong\u003e centrally.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2984\" data-end=\"3011\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3013\" data-end=\"3321\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3013\" data-end=\"3055\"\u003e\n\u003ctr data-start=\"3013\" data-end=\"3055\"\u003e\n\u003cth data-start=\"3013\" data-end=\"3023\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3023\" data-end=\"3044\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3044\" data-end=\"3055\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3070\" data-end=\"3321\"\u003e\n\u003ctr data-start=\"3070\" data-end=\"3173\"\u003e\n\u003ctd data-start=\"3070\" data-end=\"3107\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3072\" data-end=\"3106\"\u003eGnRH–LH\/FSH axis up-regulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3107\" data-end=\"3152\"\u003eEndogenous T ↑, sperm production preserved\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3152\" data-end=\"3173\"\u003eMale hypogonadism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3174\" data-end=\"3256\"\u003e\n\u003ctd data-start=\"3174\" data-end=\"3204\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3176\" data-end=\"3203\"\u003eAromatization of T → E2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3204\" data-end=\"3244\"\u003ePhysiologic estradiol for bone\/libido\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3244\" data-end=\"3256\"\u003eSystemic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3257\" data-end=\"3321\"\u003e\n\u003ctd data-start=\"3257\" data-end=\"3279\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3259\" data-end=\"3278\"\u003eSHBG modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3279\" data-end=\"3312\"\u003eMild ↑\/↔ depending on baseline\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3312\" data-end=\"3321\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3323\" data-end=\"3326\"\u003e\n\u003ch2 data-start=\"3328\" data-end=\"3350\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3352\" data-end=\"3779\"\u003e\n\u003cli data-start=\"3352\" data-end=\"3400\"\u003e\n\u003cp data-start=\"3354\" data-end=\"3400\"\u003e\u003cstrong data-start=\"3354\" data-end=\"3364\"\u003eRoute:\u003c\/strong\u003e Oral tablet (usually compounded).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3401\" data-end=\"3488\"\u003e\n\u003cp data-start=\"3403\" data-end=\"3488\"\u003e\u003cstrong data-start=\"3403\" data-end=\"3413\"\u003eOnset:\u003c\/strong\u003e \u003cstrong data-start=\"3414\" data-end=\"3438\"\u003eT rises within weeks\u003c\/strong\u003e; sperm parameters respond over \u003cstrong data-start=\"3470\" data-end=\"3485\"\u003e2–3+ months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3489\" data-end=\"3615\"\u003e\n\u003cp data-start=\"3491\" data-end=\"3615\"\u003e\u003cstrong data-start=\"3491\" data-end=\"3505\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"3506\" data-end=\"3517\"\u003eShorter\u003c\/strong\u003e than zuclomiphene (days vs weeks), reducing long tail accumulation typical of clomiphene mixes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3616\" data-end=\"3779\"\u003e\n\u003cp data-start=\"3618\" data-end=\"3779\"\u003e\u003cstrong data-start=\"3618\" data-end=\"3657\"\u003eDosing used clinically (off-label):\u003c\/strong\u003e \u003cstrong data-start=\"3658\" data-end=\"3678\"\u003e6.25–25 mg daily\u003c\/strong\u003e (common: \u003cstrong data-start=\"3688\" data-end=\"3705\"\u003e12.5–25 mg QD\u003c\/strong\u003e), or \u003cstrong data-start=\"3711\" data-end=\"3724\"\u003e25 mg QOD\u003c\/strong\u003e, titrated to \u003cstrong data-start=\"3738\" data-end=\"3758\"\u003emid-normal TT\/FT\u003c\/strong\u003e and symptom control.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3781\" data-end=\"3784\"\u003e\n\u003ch2 data-start=\"3786\" data-end=\"3822\"\u003e4. Clinical Evidence (high-level)\u003c\/h2\u003e\n\u003cul data-start=\"3824\" data-end=\"4378\"\u003e\n\u003cli data-start=\"3824\" data-end=\"4013\"\u003e\n\u003cp data-start=\"3826\" data-end=\"4013\"\u003e\u003cstrong data-start=\"3826\" data-end=\"3859\"\u003eSecondary hypogonadism (men):\u003c\/strong\u003e RCTs and open-label studies show \u003cstrong data-start=\"3893\" data-end=\"3912\"\u003eTT\/FT increases\u003c\/strong\u003e comparable to low-dose TRT, with \u003cstrong data-start=\"3946\" data-end=\"3967\"\u003eLH\/FSH maintained\u003c\/strong\u003e and \u003cstrong data-start=\"3972\" data-end=\"3998\"\u003esperm counts preserved\u003c\/strong\u003e or improved.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4014\" data-end=\"4125\"\u003e\n\u003cp data-start=\"4016\" data-end=\"4125\"\u003e\u003cstrong data-start=\"4016\" data-end=\"4033\"\u003eSymptoms\/QoL:\u003c\/strong\u003e Improvements in \u003cstrong data-start=\"4050\" data-end=\"4069\"\u003esexual function\u003c\/strong\u003e and \u003cstrong data-start=\"4074\" data-end=\"4086\"\u003evitality\u003c\/strong\u003e correlate with biochemical response.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4126\" data-end=\"4268\"\u003e\n\u003cp data-start=\"4128\" data-end=\"4268\"\u003e\u003cstrong data-start=\"4128\" data-end=\"4147\"\u003eMetabolic labs:\u003c\/strong\u003e Neutral to mildly favorable effects on \u003cstrong data-start=\"4187\" data-end=\"4217\"\u003elipids\/insulin sensitivity\u003c\/strong\u003e; far lower rates of \u003cstrong data-start=\"4238\" data-end=\"4256\"\u003eerythrocytosis\u003c\/strong\u003ethan TRT.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4269\" data-end=\"4378\"\u003e\n\u003cp data-start=\"4271\" data-end=\"4378\"\u003e\u003cstrong data-start=\"4271\" data-end=\"4292\"\u003eFemale fertility:\u003c\/strong\u003e Clomiphene citrate remains standard; enclomiphene monotherapy is \u003cstrong data-start=\"4358\" data-end=\"4377\"\u003einvestigational\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4380\" data-end=\"4664\"\u003e\n\u003cp data-start=\"4382\" data-end=\"4664\"\u003e\u003cstrong data-start=\"4382\" data-end=\"4408\"\u003eEvidence quality note:\u003c\/strong\u003e Solid \u003cstrong data-start=\"4415\" data-end=\"4433\"\u003emale endocrine\u003c\/strong\u003e data for biochemical efficacy; fewer large, long-term outcome trials than for TRT. Regulatory approval attempts in the US previously received \u003cstrong data-start=\"4576\" data-end=\"4605\"\u003ecomplete response letters\u003c\/strong\u003e; enclomiphene remains \u003cstrong data-start=\"4628\" data-end=\"4642\"\u003eunapproved\u003c\/strong\u003e as a branded product.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4666\" data-end=\"4669\"\u003e\n\u003ch2 data-start=\"4671\" data-end=\"4704\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4706\" data-end=\"5180\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4706\" data-end=\"4736\"\u003e\n\u003ctr data-start=\"4706\" data-end=\"4736\"\u003e\n\u003cth data-start=\"4706\" data-end=\"4714\" data-col-size=\"md\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"4714\" data-end=\"4726\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"4726\" data-end=\"4736\" data-col-size=\"sm\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4751\" data-end=\"5180\"\u003e\n\u003ctr data-start=\"4751\" data-end=\"4879\"\u003e\n\u003ctd data-start=\"4751\" data-end=\"4813\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"4753\" data-end=\"4812\"\u003eFunctional hypogonadism (obesity, opioids, OSA treated)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4813\" data-end=\"4855\" data-col-size=\"md\"\u003eRestore axis while preserving fertility\u003c\/td\u003e\n\u003ctd data-start=\"4855\" data-end=\"4879\" data-col-size=\"sm\"\u003eReal-world\/off-label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4880\" data-end=\"4983\"\u003e\n\u003ctd data-start=\"4880\" data-end=\"4903\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"4882\" data-end=\"4902\"\u003eAdjunct with hCG\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4903\" data-end=\"4965\" data-col-size=\"md\"\u003ehCG for intratesticular T + enclomiphene for pituitary tone\u003c\/td\u003e\n\u003ctd data-start=\"4965\" data-end=\"4983\" data-col-size=\"sm\"\u003ePractice-based\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4984\" data-end=\"5062\"\u003e\n\u003ctd data-start=\"4984\" data-end=\"5012\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"4986\" data-end=\"5011\"\u003ePost-TRT\/AAS recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5012\" data-end=\"5045\" data-col-size=\"md\"\u003eRe-engage axis with SERM ± hCG\u003c\/td\u003e\n\u003ctd data-start=\"5045\" data-end=\"5062\" data-col-size=\"sm\"\u003eObservational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5063\" data-end=\"5180\"\u003e\n\u003ctd data-start=\"5063\" data-end=\"5104\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5065\" data-end=\"5103\"\u003eMale infertility with low-normal T\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5104\" data-end=\"5151\" data-col-size=\"md\"\u003eImprove T and \u003cstrong data-start=\"5120\" data-end=\"5139\"\u003espermatogenesis\u003c\/strong\u003e before ART\u003c\/td\u003e\n\u003ctd data-start=\"5151\" data-end=\"5180\" data-col-size=\"sm\"\u003eOngoing practice research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5182\" data-end=\"5185\"\u003e\n\u003ch2 data-start=\"5187\" data-end=\"5216\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5218\" data-end=\"6236\"\u003e\n\u003cli data-start=\"5218\" data-end=\"5380\"\u003e\n\u003cp data-start=\"5220\" data-end=\"5380\"\u003e\u003cstrong data-start=\"5220\" data-end=\"5231\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"5232\" data-end=\"5244\"\u003eHeadache\u003c\/strong\u003e, \u003cstrong data-start=\"5246\" data-end=\"5261\"\u003ehot flashes\u003c\/strong\u003e, \u003cstrong data-start=\"5263\" data-end=\"5293\"\u003emood lability\/irritability\u003c\/strong\u003e, \u003cstrong data-start=\"5295\" data-end=\"5307\"\u003eGI upset\u003c\/strong\u003e, \u003cstrong data-start=\"5309\" data-end=\"5342\"\u003etransient visual disturbances\u003c\/strong\u003e (rare; caution with night driving).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5381\" data-end=\"5539\"\u003e\n\u003cp data-start=\"5383\" data-end=\"5539\"\u003e\u003cstrong data-start=\"5383\" data-end=\"5397\"\u003eEndocrine:\u003c\/strong\u003e Possible \u003cstrong data-start=\"5407\" data-end=\"5422\"\u003eE2 increase\u003c\/strong\u003e → \u003cstrong data-start=\"5425\" data-end=\"5459\"\u003ebreast tenderness\/gynecomastia\u003c\/strong\u003e in sensitive men; consider dose adjustment or \u003cstrong data-start=\"5506\" data-end=\"5521\"\u003elow-dose AI\u003c\/strong\u003e if symptomatic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5540\" data-end=\"5611\"\u003e\n\u003cp data-start=\"5542\" data-end=\"5611\"\u003e\u003cstrong data-start=\"5542\" data-end=\"5558\"\u003eHematologic:\u003c\/strong\u003e \u003cstrong data-start=\"5559\" data-end=\"5586\"\u003eErythrocytosis uncommon\u003c\/strong\u003e vs TRT, but check CBC.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5612\" data-end=\"5728\"\u003e\n\u003cp data-start=\"5614\" data-end=\"5728\"\u003e\u003cstrong data-start=\"5614\" data-end=\"5638\"\u003eThromboembolic risk:\u003c\/strong\u003e SERMs carry a \u003cstrong data-start=\"5653\" data-end=\"5677\"\u003etheoretical VTE risk\u003c\/strong\u003e (low in men but screen for history\/family risk).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5729\" data-end=\"5813\"\u003e\n\u003cp data-start=\"5731\" data-end=\"5813\"\u003e\u003cstrong data-start=\"5731\" data-end=\"5743\"\u003eHepatic:\u003c\/strong\u003e Rare transaminase elevations—obtain baseline and periodic \u003cstrong data-start=\"5802\" data-end=\"5810\"\u003eLFTs\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5814\" data-end=\"5872\"\u003e\n\u003cp data-start=\"5816\" data-end=\"5872\"\u003e\u003cstrong data-start=\"5816\" data-end=\"5826\"\u003ePsych:\u003c\/strong\u003e Anxiety\/irritability in a minority—monitor.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5873\" data-end=\"5998\"\u003e\n\u003cp data-start=\"5875\" data-end=\"5998\"\u003e\u003cstrong data-start=\"5875\" data-end=\"5886\"\u003eOcular:\u003c\/strong\u003e Very rare \u003cstrong data-start=\"5897\" data-end=\"5913\"\u003eoptic events\u003c\/strong\u003e have been described with clomiphene-class SERMs—stop if \u003cstrong data-start=\"5970\" data-end=\"5989\"\u003evisual symptoms\u003c\/strong\u003eoccur.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5999\" data-end=\"6129\"\u003e\n\u003cp data-start=\"6001\" data-end=\"6129\"\u003e\u003cstrong data-start=\"6001\" data-end=\"6023\"\u003eContraindications:\u003c\/strong\u003e \u003cstrong data-start=\"6024\" data-end=\"6048\"\u003eActive liver disease\u003c\/strong\u003e, prior \u003cstrong data-start=\"6056\" data-end=\"6063\"\u003eVTE\u003c\/strong\u003e, \u003cstrong data-start=\"6065\" data-end=\"6094\"\u003euncontrolled polycythemia\u003c\/strong\u003e, hypersensitivity to SERM class.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6130\" data-end=\"6178\"\u003e\n\u003cp data-start=\"6132\" data-end=\"6178\"\u003e\u003cstrong data-start=\"6132\" data-end=\"6146\"\u003ePregnancy:\u003c\/strong\u003e Contraindicated (SERM class).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6179\" data-end=\"6236\"\u003e\n\u003cp data-start=\"6181\" data-end=\"6236\"\u003e\u003cstrong data-start=\"6181\" data-end=\"6197\"\u003eAnti-doping:\u003c\/strong\u003e \u003cstrong data-start=\"6198\" data-end=\"6230\"\u003eSERMs are prohibited by WADA\u003c\/strong\u003e (S4).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6238\" data-end=\"6276\"\u003e\u003cstrong data-start=\"6238\" data-end=\"6276\"\u003eComparative safety\/efficacy matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6278\" data-end=\"7035\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6278\" data-end=\"6373\"\u003e\n\u003ctr data-start=\"6278\" data-end=\"6373\"\u003e\n\u003cth data-start=\"6278\" data-end=\"6288\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6288\" data-end=\"6307\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6290\" data-end=\"6306\"\u003eEnclomiphene\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6307\" data-end=\"6338\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6309\" data-end=\"6337\"\u003eClomiphene citrate (mix)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6338\" data-end=\"6362\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6340\" data-end=\"6361\"\u003eTRT (exogenous T)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6362\" data-end=\"6373\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6364\" data-end=\"6371\"\u003ehCG\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6396\" data-end=\"7035\"\u003e\n\u003ctr data-start=\"6396\" data-end=\"6529\"\u003e\n\u003ctd data-start=\"6396\" data-end=\"6410\" data-col-size=\"sm\"\u003eAxis effect\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6410\" data-end=\"6434\"\u003e\u003cstrong data-start=\"6412\" data-end=\"6433\"\u003eStimulates LH\/FSH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6434\" data-end=\"6473\"\u003eStimulates (isomer mix; longer tail)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6473\" data-end=\"6497\"\u003e\n\u003cstrong data-start=\"6475\" data-end=\"6489\"\u003eSuppresses\u003c\/strong\u003eLH\/FSH\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6497\" data-end=\"6529\"\u003eStimulates Leydig (LH-mimic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6530\" data-end=\"6639\"\u003e\n\u003ctd data-start=\"6530\" data-end=\"6542\" data-col-size=\"sm\"\u003eFertility\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6542\" data-end=\"6558\"\u003e\u003cstrong data-start=\"6544\" data-end=\"6557\"\u003ePreserved\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6558\" data-end=\"6570\"\u003ePreserved\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6570\" data-end=\"6593\"\u003e\u003cstrong data-start=\"6572\" data-end=\"6592\"\u003eOften suppressed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6593\" data-end=\"6639\"\u003ePreserved; supports spermatogenesis (±FSH)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6640\" data-end=\"6697\"\u003e\n\u003ctd data-start=\"6640\" data-end=\"6657\" data-col-size=\"sm\"\u003eErythrocytosis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6657\" data-end=\"6667\"\u003e\u003cstrong data-start=\"6659\" data-end=\"6666\"\u003eLow\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6667\" data-end=\"6677\"\u003eLow–mod\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6677\" data-end=\"6690\"\u003e\u003cstrong data-start=\"6679\" data-end=\"6689\"\u003eHigher\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6690\" data-end=\"6697\"\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6698\" data-end=\"6814\"\u003e\n\u003ctd data-start=\"6698\" data-end=\"6718\" data-col-size=\"sm\"\u003eGynecomastia risk\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6718\" data-end=\"6748\"\u003eE2-related (dose-dependent)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6748\" data-end=\"6758\"\u003eSimilar\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6758\" data-end=\"6789\"\u003eAromatization of exogenous T\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6789\" data-end=\"6814\"\u003eAromatization from ↑T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6815\" data-end=\"6909\"\u003e\n\u003ctd data-start=\"6815\" data-end=\"6839\" data-col-size=\"sm\"\u003eVisual\/neurologic AEs\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6839\" data-end=\"6857\"\u003eRare SERM-class\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6857\" data-end=\"6886\"\u003eSlightly more (zuclo tail)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6886\" data-end=\"6897\"\u003eUncommon\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"6897\" data-end=\"6909\"\u003eUncommon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6910\" data-end=\"7035\"\u003e\n\u003ctd data-start=\"6910\" data-end=\"6930\" data-col-size=\"sm\"\u003eRegulatory status\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6930\" data-end=\"6974\"\u003e\u003cstrong data-start=\"6932\" data-end=\"6973\"\u003eUnapproved; off-label via compounding\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"6974\" data-end=\"7012\"\u003eApproved (female), off-label (male)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"7012\" data-end=\"7023\"\u003eApproved\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"7023\" data-end=\"7035\"\u003eApproved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7037\" data-end=\"7040\"\u003e\n\u003ch2 data-start=\"7042\" data-end=\"7068\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7070\" data-end=\"7399\"\u003e\n\u003cli data-start=\"7070\" data-end=\"7180\"\u003e\n\u003cp data-start=\"7072\" data-end=\"7180\"\u003e\u003cstrong data-start=\"7072\" data-end=\"7096\"\u003eNot FDA\/EMA-approved\u003c\/strong\u003e as a branded product for male hypogonadism (prior NDA efforts were not approved).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7181\" data-end=\"7399\"\u003e\n\u003cp data-start=\"7183\" data-end=\"7399\"\u003eMale hypogonadism treatment guidelines typically endorse \u003cstrong data-start=\"7240\" data-end=\"7247\"\u003eTRT\u003c\/strong\u003e for confirmed organic deficiency; \u003cstrong data-start=\"7282\" data-end=\"7317\"\u003eSERMs (clomiphene\/enclomiphene)\u003c\/strong\u003e are discussed \u003cstrong data-start=\"7332\" data-end=\"7345\"\u003eoff-label\u003c\/strong\u003e for \u003cstrong data-start=\"7350\" data-end=\"7398\"\u003esecondary hypogonadism with fertility intent\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7401\" data-end=\"7404\"\u003e\n\u003ch2 data-start=\"7406\" data-end=\"7443\"\u003e8. Practical Use (clinic playbook)\u003c\/h2\u003e\n\u003cul data-start=\"7445\" data-end=\"8476\"\u003e\n\u003cli data-start=\"7445\" data-end=\"7646\"\u003e\n\u003cp data-start=\"7447\" data-end=\"7646\"\u003e\u003cstrong data-start=\"7447\" data-end=\"7474\"\u003eWho’s a good candidate?\u003c\/strong\u003e Men with \u003cstrong data-start=\"7484\" data-end=\"7521\"\u003esecondary\/functional hypogonadism\u003c\/strong\u003e (low morning \u003cstrong data-start=\"7535\" data-end=\"7567\"\u003eTT\/FT with low\/normal LH\/FSH\u003c\/strong\u003e), desiring \u003cstrong data-start=\"7579\" data-end=\"7605\"\u003efertility preservation\u003c\/strong\u003e, without major SERM contraindications.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7647\" data-end=\"7828\"\u003e\n\u003cp data-start=\"7649\" data-end=\"7828\"\u003e\u003cstrong data-start=\"7649\" data-end=\"7670\"\u003eBaseline work-up:\u003c\/strong\u003e \u003cstrong data-start=\"7671\" data-end=\"7727\"\u003eTT\/FT (2 mornings), LH\/FSH, E2, SHBG, prolactin, TSH\u003c\/strong\u003e, \u003cstrong data-start=\"7729\" data-end=\"7736\"\u003eCBC\u003c\/strong\u003e, \u003cstrong data-start=\"7738\" data-end=\"7746\"\u003eLFTs\u003c\/strong\u003e, semen analysis if fertility relevant; assess \u003cstrong data-start=\"7793\" data-end=\"7800\"\u003eOSA\u003c\/strong\u003e, meds (opioids), obesity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7829\" data-end=\"7968\"\u003e\n\u003cp data-start=\"7831\" data-end=\"7968\"\u003e\u003cstrong data-start=\"7831\" data-end=\"7842\"\u003eDosing:\u003c\/strong\u003e Start \u003cstrong data-start=\"7849\" data-end=\"7863\"\u003e12.5 mg QD\u003c\/strong\u003e (range 6.25–25 mg). Recheck labs at \u003cstrong data-start=\"7900\" data-end=\"7913\"\u003e4–6 weeks\u003c\/strong\u003e; titrate to \u003cstrong data-start=\"7926\" data-end=\"7946\"\u003emid-normal TT\/FT\u003c\/strong\u003e and symptom relief.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7969\" data-end=\"8153\"\u003e\n\u003cp data-start=\"7971\" data-end=\"8153\"\u003e\u003cstrong data-start=\"7971\" data-end=\"8017\"\u003eFollow-up (q8–12 wks early, then q3–6 mo):\u003c\/strong\u003e \u003cstrong data-start=\"8018\" data-end=\"8039\"\u003eTT\/FT, E2, LH\/FSH\u003c\/strong\u003e, \u003cstrong data-start=\"8041\" data-end=\"8048\"\u003eCBC\u003c\/strong\u003e, \u003cstrong data-start=\"8050\" data-end=\"8058\"\u003eLFTs\u003c\/strong\u003e, BP\/weight, \u003cstrong data-start=\"8071\" data-end=\"8083\"\u003esymptoms\u003c\/strong\u003e; semen parameters every \u003cstrong data-start=\"8108\" data-end=\"8122\"\u003e3–6 months\u003c\/strong\u003e if fertility is an endpoint.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8154\" data-end=\"8315\"\u003e\n\u003cp data-start=\"8156\" data-end=\"8315\"\u003e\u003cstrong data-start=\"8156\" data-end=\"8169\"\u003eAdjuncts:\u003c\/strong\u003e If \u003cstrong data-start=\"8173\" data-end=\"8179\"\u003eE2\u003c\/strong\u003e climbs with symptoms, consider dose reduction, \u003cstrong data-start=\"8227\" data-end=\"8241\"\u003eEOD dosing\u003c\/strong\u003e, or \u003cstrong data-start=\"8246\" data-end=\"8261\"\u003elow-dose AI\u003c\/strong\u003e; if T response is blunted, consider \u003cstrong data-start=\"8298\" data-end=\"8312\"\u003eadd-on hCG\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8316\" data-end=\"8476\"\u003e\n\u003cp data-start=\"8318\" data-end=\"8476\"\u003e\u003cstrong data-start=\"8318\" data-end=\"8335\"\u003eStop\/hold if:\u003c\/strong\u003e Visual symptoms, VTE signs, persistent mood instability, significant LFT rise, or absent biochemical\/clinical response after adequate trial.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8478\" data-end=\"8481\"\u003e\n\u003ch3 data-start=\"8483\" data-end=\"8506\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8508\" data-end=\"9096\"\u003e\n\u003cli data-start=\"8508\" data-end=\"8647\"\u003e\n\u003cp data-start=\"8510\" data-end=\"8647\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism — SERM therapy for male secondary hypogonadism; enclomiphene vs clomiphene pharmacology.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8648\" data-end=\"8762\"\u003e\n\u003cp data-start=\"8650\" data-end=\"8762\"\u003eFertility and Sterility; Andrology — Effects on \u003cstrong data-start=\"8698\" data-end=\"8717\"\u003espermatogenesis\u003c\/strong\u003e, semen parameters, and fertility outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8763\" data-end=\"8897\"\u003e\n\u003cp data-start=\"8765\" data-end=\"8897\"\u003eEndocrine Reviews; Clinical Endocrinology — Algorithms for diagnosing functional hypogonadism and fertility-preserving strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8898\" data-end=\"9026\"\u003e\n\u003cp data-start=\"8900\" data-end=\"9026\"\u003eUrology; BJU International — Comparative data: \u003cstrong data-start=\"8947\" data-end=\"8970\"\u003eenclomiphene vs TRT\u003c\/strong\u003e on TT\/FT, LH\/FSH, hematologic and metabolic outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9027\" data-end=\"9096\"\u003e\n\u003cp data-start=\"9029\" data-end=\"9096\"\u003eDrug Testing \u0026amp; Analysis; WADA Code — \u003cstrong data-start=\"9066\" data-end=\"9086\"\u003eSERM prohibition\u003c\/strong\u003e in sport.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684865438034,"sku":null,"price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Enclomiphene_12.5mg.png?v=1770834941","url":"https:\/\/sciencepeptideslab.com\/products\/enclomiphene-50x12-5mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}